PubMed:29946148 JSONTXT

{"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":100,"end":115},"obj":"Disease"},{"id":"T2","span":{"begin":288,"end":303},"obj":"Disease"},{"id":"T3","span":{"begin":305,"end":308},"obj":"Disease"},{"id":"T4","span":{"begin":514,"end":517},"obj":"Disease"},{"id":"T5","span":{"begin":684,"end":687},"obj":"Disease"},{"id":"T6","span":{"begin":1021,"end":1024},"obj":"Disease"},{"id":"T7","span":{"begin":1372,"end":1375},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005148"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005148"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005148"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005148"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0018960"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0018960"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005148"}],"text":"Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes.\nTo investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only therapy. We analyzed data from our two randomized, controlled open-label trials. Newly diagnoses T2D patients were randomized assigned to receive either CSII therapy or Met + CSII therapy for 4 weeks. Subjects were subjected to a 4-day continuous glucose monitoring (CGM) at the endpoint. Insulin doses and GV profiles were analyzed. The primary endpoint was differences in insulin doses and GV between the two groups. A total of 188 subjects were admitted as inpatients. Subjects in metformin add-on therapy required significantly lower total, basal and bolus insulin doses than those of control group. CGM data showed that patients in Met + CSII group exhibited significant reduction in the 24-hr mean amplitude of glycemic excursions (MAGE), the standard deviation, and the coefficient of variation compared to those of control group. Our data suggest that metformin add-on to CSII therapy leads to a significant reduction in insulin doses required by T2D patients to control glycemic variations."}

{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":972,"end":977},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0012113"}],"text":"Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes.\nTo investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only therapy. We analyzed data from our two randomized, controlled open-label trials. Newly diagnoses T2D patients were randomized assigned to receive either CSII therapy or Met + CSII therapy for 4 weeks. Subjects were subjected to a 4-day continuous glucose monitoring (CGM) at the endpoint. Insulin doses and GV profiles were analyzed. The primary endpoint was differences in insulin doses and GV between the two groups. A total of 188 subjects were admitted as inpatients. Subjects in metformin add-on therapy required significantly lower total, basal and bolus insulin doses than those of control group. CGM data showed that patients in Met + CSII group exhibited significant reduction in the 24-hr mean amplitude of glycemic excursions (MAGE), the standard deviation, and the coefficient of variation compared to those of control group. Our data suggest that metformin add-on to CSII therapy leads to a significant reduction in insulin doses required by T2D patients to control glycemic variations."}

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T10","span":{"begin":901,"end":910},"obj":"CI"},{"id":"T11","span":{"begin":1277,"end":1286},"obj":"CI"},{"id":"T2","span":{"begin":69,"end":76},"obj":"CI"},{"id":"T4","span":{"begin":262,"end":269},"obj":"CI"},{"id":"T5","span":{"begin":791,"end":798},"obj":"CI"},{"id":"T6","span":{"begin":978,"end":985},"obj":"CI"},{"id":"T7","span":{"begin":1346,"end":1353},"obj":"CI"},{"id":"T8","span":{"begin":0,"end":9},"obj":"CI"},{"id":"T9","span":{"begin":140,"end":149},"obj":"CI"},{"id":"T12","span":{"begin":206,"end":210},"obj":"CI"},{"id":"T13","span":{"begin":586,"end":590},"obj":"CI"},{"id":"T14","span":{"begin":1054,"end":1058},"obj":"CI"},{"id":"T15","span":{"begin":211,"end":216},"obj":"CI"},{"id":"T16","span":{"begin":591,"end":596},"obj":"CI"},{"id":"T17","span":{"begin":1059,"end":1064},"obj":"CI"},{"id":"T18","span":{"begin":164,"end":195},"obj":"CI"},{"id":"T19","span":{"begin":17,"end":48},"obj":"CI"},{"id":"T20","span":{"begin":305,"end":308},"obj":"DP"},{"id":"T21","span":{"begin":514,"end":517},"obj":"DP"},{"id":"T22","span":{"begin":1372,"end":1375},"obj":"DP"},{"id":"T23","span":{"begin":288,"end":303},"obj":"DP"},{"id":"T24","span":{"begin":100,"end":115},"obj":"DP"},{"id":"T25","span":{"begin":1297,"end":1301},"obj":"CI"},{"id":"T26","span":{"begin":407,"end":411},"obj":"CI"},{"id":"T27","span":{"begin":570,"end":574},"obj":"CI"}],"text":"Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes.\nTo investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only therapy. We analyzed data from our two randomized, controlled open-label trials. Newly diagnoses T2D patients were randomized assigned to receive either CSII therapy or Met + CSII therapy for 4 weeks. Subjects were subjected to a 4-day continuous glucose monitoring (CGM) at the endpoint. Insulin doses and GV profiles were analyzed. The primary endpoint was differences in insulin doses and GV between the two groups. A total of 188 subjects were admitted as inpatients. Subjects in metformin add-on therapy required significantly lower total, basal and bolus insulin doses than those of control group. CGM data showed that patients in Met + CSII group exhibited significant reduction in the 24-hr mean amplitude of glycemic excursions (MAGE), the standard deviation, and the coefficient of variation compared to those of control group. Our data suggest that metformin add-on to CSII therapy leads to a significant reduction in insulin doses required by T2D patients to control glycemic variations."}

{"project":"yaoziqian_800_3","denotations":[{"id":"T1","span":{"begin":0,"end":9},"obj":"CI"},{"id":"T10","span":{"begin":288,"end":303},"obj":"DP"},{"id":"T11","span":{"begin":305,"end":308},"obj":"DP"},{"id":"T12","span":{"begin":514,"end":517},"obj":"DP"},{"id":"T13","span":{"begin":1372,"end":1375},"obj":"DP"},{"id":"T14","span":{"begin":206,"end":210},"obj":"CI"},{"id":"T15","span":{"begin":586,"end":590},"obj":"CI"},{"id":"T16","span":{"begin":1054,"end":1058},"obj":"CI"},{"id":"T17","span":{"begin":211,"end":216},"obj":"CI"},{"id":"T18","span":{"begin":591,"end":596},"obj":"CI"},{"id":"T19","span":{"begin":1059,"end":1064},"obj":"CI"},{"id":"T20","span":{"begin":407,"end":411},"obj":"CI"},{"id":"T21","span":{"begin":570,"end":574},"obj":"CI"},{"id":"T22","span":{"begin":1297,"end":1301},"obj":"CI"},{"id":"T3","span":{"begin":69,"end":76},"obj":"CI"},{"id":"T5","span":{"begin":262,"end":269},"obj":"CI"},{"id":"T6","span":{"begin":791,"end":798},"obj":"CI"},{"id":"T7","span":{"begin":978,"end":985},"obj":"CI"},{"id":"T8","span":{"begin":1346,"end":1353},"obj":"CI"},{"id":"T9","span":{"begin":100,"end":115},"obj":"DP"},{"id":"T23","span":{"begin":17,"end":48},"obj":"CI"},{"id":"T24","span":{"begin":164,"end":195},"obj":"CI"},{"id":"T25","span":{"begin":140,"end":149},"obj":"CI"},{"id":"T26","span":{"begin":901,"end":910},"obj":"CI"},{"id":"T27","span":{"begin":1277,"end":1286},"obj":"CI"}],"text":"Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes.\nTo investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only therapy. We analyzed data from our two randomized, controlled open-label trials. Newly diagnoses T2D patients were randomized assigned to receive either CSII therapy or Met + CSII therapy for 4 weeks. Subjects were subjected to a 4-day continuous glucose monitoring (CGM) at the endpoint. Insulin doses and GV profiles were analyzed. The primary endpoint was differences in insulin doses and GV between the two groups. A total of 188 subjects were admitted as inpatients. Subjects in metformin add-on therapy required significantly lower total, basal and bolus insulin doses than those of control group. CGM data showed that patients in Met + CSII group exhibited significant reduction in the 24-hr mean amplitude of glycemic excursions (MAGE), the standard deviation, and the coefficient of variation compared to those of control group. Our data suggest that metformin add-on to CSII therapy leads to a significant reduction in insulin doses required by T2D patients to control glycemic variations."}

{"project":"HP-phenotype","denotations":[{"id":"T1","span":{"begin":100,"end":115},"obj":"Phenotype"},{"id":"T2","span":{"begin":288,"end":303},"obj":"Phenotype"},{"id":"T3","span":{"begin":305,"end":308},"obj":"Phenotype"},{"id":"T4","span":{"begin":514,"end":517},"obj":"Phenotype"},{"id":"T5","span":{"begin":1372,"end":1375},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0005978"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"HP:0005978"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"HP:0005978"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"HP:0005978"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"HP:0005978"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes.\nTo investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only therapy. We analyzed data from our two randomized, controlled open-label trials. Newly diagnoses T2D patients were randomized assigned to receive either CSII therapy or Met + CSII therapy for 4 weeks. Subjects were subjected to a 4-day continuous glucose monitoring (CGM) at the endpoint. Insulin doses and GV profiles were analyzed. The primary endpoint was differences in insulin doses and GV between the two groups. A total of 188 subjects were admitted as inpatients. Subjects in metformin add-on therapy required significantly lower total, basal and bolus insulin doses than those of control group. CGM data showed that patients in Met + CSII group exhibited significant reduction in the 24-hr mean amplitude of glycemic excursions (MAGE), the standard deviation, and the coefficient of variation compared to those of control group. Our data suggest that metformin add-on to CSII therapy leads to a significant reduction in insulin doses required by T2D patients to control glycemic variations."}

{"project":"CL-cell","denotations":[{"id":"T1","span":{"begin":962,"end":967},"obj":"Cell"}],"attributes":[{"id":"A1","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0002324"}],"text":"Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes.\nTo investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only therapy. We analyzed data from our two randomized, controlled open-label trials. Newly diagnoses T2D patients were randomized assigned to receive either CSII therapy or Met + CSII therapy for 4 weeks. Subjects were subjected to a 4-day continuous glucose monitoring (CGM) at the endpoint. Insulin doses and GV profiles were analyzed. The primary endpoint was differences in insulin doses and GV between the two groups. A total of 188 subjects were admitted as inpatients. Subjects in metformin add-on therapy required significantly lower total, basal and bolus insulin doses than those of control group. CGM data showed that patients in Met + CSII group exhibited significant reduction in the 24-hr mean amplitude of glycemic excursions (MAGE), the standard deviation, and the coefficient of variation compared to those of control group. Our data suggest that metformin add-on to CSII therapy leads to a significant reduction in insulin doses required by T2D patients to control glycemic variations."}